Orchid Pharma Limited Receives Reserve Order for Dhanuka Laboratories Merger
Orchid Pharma Limited has received a reserved order from the National Company Law Tribunal (NCLT) regarding the scheme of amalgamation with Dhanuka Laboratories Limited. The order was reserved for pronouncement on March 18, 2026.The amalgamation involves Dhanuka Laboratories Limited and Orchid Pharma Limited, along with their respective shareholders and creditors.
Orchid Pharma Limited will provide updates to the National Stock Exchange of India Limited and the BSE Limited, as well as make the information available on the company’s website, upon receipt of the NCLT order.
Manish Dhanuka, Managing Director of Orchid Pharma Limited, confirmed the development.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.